Cumberland Partners Ltd Makes New $1.50 Million Investment in Zoetis Inc. (NYSE:ZTS)

Cumberland Partners Ltd purchased a new stake in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 9,200 shares of the company’s stock, valued at approximately $1,499,000.

Several other institutional investors have also recently made changes to their positions in the stock. Darwin Wealth Management LLC acquired a new position in Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis during the third quarter worth approximately $33,000. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $156.92 on Thursday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company’s 50-day moving average is $167.29 and its 200 day moving average is $178.29. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market capitalization of $70.27 billion, a P/E ratio of 28.69, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. On average, equities research analysts forecast that Zoetis Inc. will post 6.06 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Analyst Ratings Changes

Several research firms have weighed in on ZTS. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Piper Sandler dropped their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Finally, Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average target price of $214.90.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.